Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Thorax
|
November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Elena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.
Disease Models & Mechanisms
|
December 6, 2021
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
Karmele Valencia, Cristina Sainz, Cristina Bértolo, et al.
Cancer Immunology Research
|
December 12, 2024
The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response
Yaiza Senent, Ana Remírez, David Repáraz, et al.
Scientific Reports
|
October 30, 2019
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Maria Villalba, Esther Redin, Francisco Exposito, et al.
Journal for Immunotherapy of Cancer
|
March 4, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Esther Redin, Irati Garmendia, Teresa Lozano, et al.
Cancer Immunology Research
|
April 28, 2026
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance
Sora Suzuki, Bojidar Kandar, Catrina Ting, et al.
Cell Death & Disease
|
November 3, 2024
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Francisco Exposito, Miriam Redrado, Diego Serrano, et al.
Nature Immunology
|
October 13, 2019
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Cancer Discovery
|
December 23, 2020
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
Vicente Fresquet, Maria J Garcia-Barchino, Marta Larrayoz, et al.
Nature Immunology
|
September 29, 2019
'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Thorax
|
November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Elena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.
Disease Models & Mechanisms
|
December 6, 2021
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
Karmele Valencia, Cristina Sainz, Cristina Bértolo, et al.
Cancer Immunology Research
|
December 12, 2024
The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response
Yaiza Senent, Ana Remírez, David Repáraz, et al.
Scientific Reports
|
October 30, 2019
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Maria Villalba, Esther Redin, Francisco Exposito, et al.
Journal for Immunotherapy of Cancer
|
March 4, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Esther Redin, Irati Garmendia, Teresa Lozano, et al.
Cancer Immunology Research
|
April 28, 2026
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance
Sora Suzuki, Bojidar Kandar, Catrina Ting, et al.
Cell Death & Disease
|
November 3, 2024
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Francisco Exposito, Miriam Redrado, Diego Serrano, et al.
Nature Immunology
|
October 13, 2019
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Cancer Discovery
|
December 23, 2020
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
Vicente Fresquet, Maria J Garcia-Barchino, Marta Larrayoz, et al.
Nature Immunology
|
September 29, 2019
'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Page
of 10